0000000000524359

AUTHOR

Leonardi

showing 2 related works from this author

Antiproliferative and chemomodulatory effects of interferon-γ on doxorubicin-sensitive and -resistant tumor cell lines

1993

Biological agents might offer various therapeutic opportunities in the treatment of cancer, including a direct and/or host-mediated antiproliferative effect and also the possibility to favorably modulate tumor resistance to antineoplastic drugs. We studied the in vitro antiproliferative effects of interferon (IFN)-gamma on the mouse B16 melanoma and Friend erythroleukemia, and the human K562 erythroleukemia, as doxorubicin (DXR)-sensitive and -resistant (multidrug resistant) variants. These effects were marked in B16 melanoma and rather slight in K562 erythroleukemia, without any difference between the DXR-sensitive and -resistant lines. The chemosensitive variant of Friend erythroleukemia …

Antimetabolites AntineoplasticCancer Researchmedicine.medical_treatmentDrug ResistanceMelanoma ExperimentalInterferon-gammaMicechemistry.chemical_compoundInterferonMethionine Sulfoximinehemic and lymphatic diseasesTumor Cells CulturedmedicineAnimalsHumansCytotoxic T cellPharmacology (medical)DoxorubicinButhionine sulfoximineInterferon gammaButhionine SulfoximinePharmacologyGlutathioneFriend murine leukemia virusCytokineOncologychemistryDoxorubicinCell cultureCancer researchLeukemia Erythroblastic AcuteCell Divisionmedicine.drugK562 cellsAnti-Cancer Drugs
researchProduct

The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs)

2017

GynecologyOncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicinemedicineRetrospective cohort studyHematologymedicine.diseasebusinessER2-positive (HER2+ve) breast cancer (BC) brain metastases (BMs)
researchProduct